🔎 Trials Near Me

Dachaigh › Ailse Endometrial › Texas

Sgrùdaidhean clionaigeach Ailse Endometrial ann an Texas

Tha 90 sgrùdaidhean airson Ailse Endometrial a’ lorg phàirtichean aig làraichean ann an Texas.

Bailtean ann an Texas

Teacsa sgrùdaidh oifigeil (Beurla)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Hendrick Medical Center, Abilene
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • Lyndon Baines Johnson General Hospital, Houston
  • agus 2 a bharrachd
A’ fastadhÌre 2
Gach aois · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05564377

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Houston
A’ fastadhÌre 1/2
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05797168

A Study of PHST001 in Advanced Solid Tumors

  • START Center for Cancer Research - Texas, Fort Worth
  • MD Anderson Cancer Center, Houston
  • NEXT Oncology - Dallas, Irving
  • agus 2 a bharrachd
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06840886

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • NEXT Austin, Austin
  • START Center for Clinical Research, Fort Worth
  • University of Texas MD Anderson Cancer Center, Houston
  • agus 1 a bharrachd
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06270706

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • New Experimental Therapeutics - NEXT Oncology, Austin
  • Texas Oncology, Bedford
  • UT Southwest Simmons Cancer Center, Dallas
  • agus 2 a bharrachd
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06760819

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06172478

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • NEXT Oncology, Austin
  • UT Southwestern, Dallas
A’ fastadhÌre 1
Aoisean 19 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06586957

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  • MD Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07189871

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Total Women's Care of the Heights, Houston
  • Medical Colleagues of Texas, LLP, Katy
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 29 Sult 2026 · NCT05051722

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Dallas
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05867251

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • agus 1 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 28 Sult 2026 · NCT05112601

DESTINY-PANTUMOUR04

  • Research Site, Dallas
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07124000

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 25 Sult 2026 · NCT03564340

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Dallas
  • Research Site, Galveston
  • Research Site, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06218914

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • M.D. Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 24 Sult 2026 · NCT05640999

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Houston
A’ fastadhÌre 2
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT05489211

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Texas Oncology - DFW (Sammons CC), Dallas
  • MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07114601

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  • START Dallas Fort Worth, Fort Worth
  • University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07262619

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • MD Anderson, Houston
  • NEXT Dallas, Irving
  • NEXT Oncology San Antonio, San Antonio
  • agus 1 a bharrachd
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Oncology Consultants, P.A., Houston
  • University of Texas M.D. Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT05983432

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  • Texas Oncology, P.A., Tyler
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 17 Sult 2026 · NCT06340568

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  • Texas Oncology - DFW ( Site 8004), Fort Worth
  • Houston Methodist Hospital ( Site 6057), Houston
  • Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio
  • agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 17 Sult 2026 · NCT06952504

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • MD Anderson Cancer Center, Houston
  • START Center for Cancer Research, San Antonio
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07109726

Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women

  • MD Anderson Cancer Center, Houston
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 16 Sult 2026 · NCT06409052

Sentinel Node Biopsy in Endometrial Cancer

  • Houston Methodist Hospital, Houston
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 15 Sult 2026 · NCT04073706

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • UT Southwestern Medical Center, Dallas
  • DHR Health Advance Care Center, Edinburg
  • The Center for Cancer and Blood Disorders, Forth Worth
  • agus 1 a bharrachd
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT05059444

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT05123482

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Start - Dfw, Fort Worth
  • Oncology Consultants, Houston
  • START - San Antonio, San Antonio
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT06293898

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • TX Onc - Arlington North, Arlington
  • USOR - Texas Oncology, Austin
  • USOR - Texas Oncology, Austin
  • agus 14 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 9 Sult 2026 · NCT07166094

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The University of Texas - MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT06400472

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

  • MD Anderson Cancer Center, Houston
  • NEXT Oncology, Irving
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 3 Sult 2026 · NCT07755436

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

  • SCRI at Mary Crowley, Dallas
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT06515613

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  • Research Site, Austin
  • Research Site, Fort Worth
  • Research Site, Houston
  • agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 3 Sult 2026 · NCT06989112

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • M. D. Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07216105

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

  • NEXT Austin, Austin
  • NEXT San Antonio, San Antonio
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 27 Lùna 2026 · NCT07227168

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

  • NEXT Austin, Austin
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Lùna 2026 · NCT07383506

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A’ fastadhÌre 1/2
12 Months – 30 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04851119

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • University of Texas, MD Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Banairean · Air ùrachadh 21 Lùna 2026 · NCT05548296

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • MD Anderson, Houston
  • UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Lùna 2026 · NCT06774963

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.